查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1523147

癌症治疗 ADC（抗体药物复合体）市场报告：到 2030 年的趋势、预测和竞争分析

Cancer Antibody Drug Conjugates Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

癌症治疗 ADC（抗体药物复合体）的趋势和预测

2030年，全球癌症药物ADC市场预计将达到209亿美元，2024年至2030年的复合年增长率为15.6%。该市场的主要驱动力是全球癌症发病率不断上升、偶联技术和抗体工程的持续进步以及研发 (R&D) 支出的增加。全球抗癌药物ADC市场前景广阔，血液学、乳癌、卵巢、肺癌、皮肤癌、脑癌等市场充满机会。

癌症治疗 ADC（按细分市场）

该研究按产品、应用、技术、最终用途行业和地区对全球癌症药物 ADC 进行了预测。

癌症药物ADC市场洞察

Lucintel 预测，由于癌症发生率的增加以及 ADC 在癌症治疗中的使用，kadcyla 将在预测期内经历最高的增长。

在这个市场中，由于全球乳癌盛行率不断上升，乳癌将继续成为最大的细分市场。

由于主要行业参与者加强战略力度和有利的地方政府计划，预计亚太地区将在预测期内实现最高增长。

常问问题

Q1.市场规模为：

A1. 至2030年，全球癌症药物ADC市场预计将达到209亿美元。

Q2.市场成长预测是多少：

A2. 2024年至2030年，全球癌症药物ADC市场预计将以15.6%的复合年增长率成长。

Q3.影响市场成长的主要驱动因素是：

A3. 该市场的主要驱动力是全球癌症发生率的增加、偶联技术和抗体工程的持续发展以及研发支出的增加。

Q4.市场的主要细分市场是：

A4. 癌症 ADC 市场前景广阔，血癌、乳癌、卵巢癌、肺癌、皮肤癌和脑癌市场充满机会。

Q5.市场的主要企业是：

A5. 主要抗癌药物ADC公司如下：

  • Seagen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Pfizer
  • Gilead Sciences
  • Daiichi Sankyo Company
  • GlaxoSmithKline
  • Astellas Pharma
  • ADC Therapeutics

Q6.未来最大的细分市场是什么？

A6.Lucintel预测，由于癌症发生率上升以及ADC在癌症治疗中的使用，kadcyla将在预测期内经历最高增长。

Q7. 未来五年预计哪些地区的市场成长最大？

由于主要产业参与者加强战略力度和有利的地方政府计划，预计 A7.APAC 将在预测期内实现最高成长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章 全球抗癌药物ADC市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球癌症治疗ADC市场趋势（2018-2023）与预测（2024-2030）
  • 全球癌症药物 ADC 市场（按产品）
    • Kadcyla
    • Enhertu
    • Adcetris
    • Padcev
    • Trodelvy
    • Polivy
    • 其他的
  • 全球癌症药物 ADC 市场（按应用）
    • 血癌
    • 乳癌
    • 卵巢癌
    • 肺癌
    • 皮肤癌
    • 脑肿瘤
    • 其他的
  • 按技术分類的全球癌症药物 ADC 市场
    • 切割类型
    • 非切削型
  • 按最终用途行业分類的全球癌症药物 ADC 市场
    • 医院
    • 专科诊所
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球癌症药物 ADC 市场（按地区）
  • 北美抗癌药物ADC市场
  • 欧洲抗癌药物ADC市场
  • 亚太地区抗癌药物ADC市场
  • 其他地区抗癌药物ADC市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
  • 全球抗癌药物ADC市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球抗癌药物ADC市场产能
    • 全球抗癌药物ADC市场併购及合资
    • 认证和许可

第七章主要企业概况

  • Seagen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Pfizer
  • Gilead Sciences
  • Daiichi Sankyo Company
  • GlaxoSmithKline
  • Astellas Pharma
  • ADC Therapeutics
简介目录

Cancer Antibody Drug Conjugates Trends and Forecast

The future of the global cancer antibody drug conjugates market looks promising with opportunities in the blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, and brain tumor markets. The global cancer antibody drug conjugates market is expected to reach an estimated $20.9 billion by 2030 with a CAGR of 15.6% from 2024 to 2030. The major drivers for this market are growing incidence of cancer worldwide, continuous developments in conjugation technology and antibody engineering, and increased spending on research and development (R&D) initiatives.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Cancer Antibody Drug Conjugates by Segment

The study includes a forecast for the global cancer antibody drug conjugates by product, application, technology, end use industry, and region.

Cancer Antibody Drug Conjugates Market by Product [Shipment Analysis by Value from 2018 to 2030]:

  • Kadcyla
  • Enhertu
  • Adcetris
  • Padcev
  • Trodelvy
  • Polivy
  • Others

Cancer Antibody Drug Conjugates Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Cancer
  • Breast Cancer
  • Ovary Cancer
  • Lung Cancer
  • Skin Cancer
  • Brain Tumor
  • Others

Cancer Antibody Drug Conjugates Market by Technology [Shipment Analysis by Value from 2018 to 2030]:

  • Cleavable
  • Non-Cleavable

Cancer Antibody Drug Conjugates Market by End Use Industry [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Others

Cancer Antibody Drug Conjugates Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Antibody Drug Conjugates Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer antibody drug conjugates companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer antibody drug conjugates companies profiled in this report include-

  • Seagen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Pfizer
  • Gilead Sciences
  • Daiichi Sankyo Company
  • GlaxoSmithKline
  • Astellas Pharma
  • ADC Therapeutics

Cancer Antibody Drug Conjugates Market Insights

Lucintel forecasts that kadcyla is expected to witness the highest growth over the forecast period due to growth in the incidence of cancer and the usage of ADCs in cancer therapy.

Within this market, breast cancer will remain the largest segment due to increasing prevalence of breast cancer across the globe.

APAC is expected to witness the highest growth over the forecast period due to growing strategic efforts by major industry participants and advantageous regional government programs.

Features of the Global Cancer Antibody Drug Conjugates Market

Market Size Estimates: Cancer antibody drug conjugates market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer antibody drug conjugates market size by product, application, technology, end use industry, and region in terms of value ($B).

Regional Analysis: Cancer antibody drug conjugates market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product, application, technology, end use industry, and regions for the cancer antibody drug conjugates market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer antibody drug conjugates market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cancer antibody drug conjugates market size?

Answer: The global cancer antibody drug conjugates market is expected to reach an estimated $20.9 billion by 2030.

Q2. What is the growth forecast for cancer antibody drug conjugates market?

Answer: The global cancer antibody drug conjugates market is expected to grow with a CAGR of 15.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cancer antibody drug conjugates market?

Answer: The major drivers for this market are growing incidence of cancer worldwide, continuous developments in conjugation technology and antibody engineering and increased spending on research and development (R&D) initiatives.

Q4. What are the major segments for cancer antibody drug conjugates market?

Answer: The future of the cancer antibody drug conjugates market looks promising with opportunities in the blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, and brain tumor markets.

Q5. Who are the key cancer antibody drug conjugates market companies?

Answer: Some of the key cancer antibody drug conjugates companies are as follows:

  • Seagen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Pfizer
  • Gilead Sciences
  • Daiichi Sankyo Company
  • GlaxoSmithKline
  • Astellas Pharma
  • ADC Therapeutics

Q6. Which cancer antibody drug conjugates market segment will be the largest in future?

Answer: Lucintel forecasts that kadcyla is expected to witness the highest growth over the forecast period due to growth in the incidence of cancer and the usage of ADCs in cancer therapy.

Q7. In cancer antibody drug conjugates market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness the highest growth over the forecast period due to growing strategic efforts by major industry participants and advantageous regional government programs.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer antibody drug conjugates market by product (kadcyla, enhertu, adcetris, padcev, trodelvy, polivy, and others), application (blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, brain tumor, and others), technology (cleavable and non-cleavable), end use industry (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Antibody Drug Conjugates Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Antibody Drug Conjugates Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Antibody Drug Conjugates Market by Product
    • 3.3.1: Kadcyla
    • 3.3.2: Enhertu
    • 3.3.3: Adcetris
    • 3.3.4: Padcev
    • 3.3.5: Trodelvy
    • 3.3.6: Polivy
    • 3.3.7: Others
  • 3.4: Global Cancer Antibody Drug Conjugates Market by Application
    • 3.4.1: Blood Cancer
    • 3.4.2: Breast Cancer
    • 3.4.3: Ovary Cancer
    • 3.4.4: Lung Cancer
    • 3.4.5: Skin Cancer
    • 3.4.6: Brain Tumor
    • 3.4.7: Others
  • 3.5: Global Cancer Antibody Drug Conjugates Market by Technology
    • 3.5.1: Cleavable
    • 3.5.2: Non-cleavable
  • 3.6: Global Cancer Antibody Drug Conjugates Market by End Use Industry
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Antibody Drug Conjugates Market by Region
  • 4.2: North American Cancer Antibody Drug Conjugates Market
    • 4.2.1: North American Cancer Antibody Drug Conjugates Market by Product: Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others
    • 4.2.2: North American Cancer Antibody Drug Conjugates Market by Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others
  • 4.3: European Cancer Antibody Drug Conjugates Market
    • 4.3.1: European Cancer Antibody Drug Conjugates Market by Product: Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others
    • 4.3.2: European Cancer Antibody Drug Conjugates Market by Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others
  • 4.4: APAC Cancer Antibody Drug Conjugates Market
    • 4.4.1: APAC Cancer Antibody Drug Conjugates Market by Product: Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others
    • 4.4.2: APAC Cancer Antibody Drug Conjugates Market by Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others
  • 4.5: ROW Cancer Antibody Drug Conjugates Market
    • 4.5.1: ROW Cancer Antibody Drug Conjugates Market by Product: Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others
    • 4.5.2: ROW Cancer Antibody Drug Conjugates Market by Application: Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by Product
    • 6.1.2: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by Application
    • 6.1.3: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by Technology
    • 6.1.4: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by End Use Industry
    • 6.1.5: Growth Opportunities for the Global Cancer Antibody Drug Conjugates Market by Region
  • 6.2: Emerging Trends in the Global Cancer Antibody Drug Conjugates Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Antibody Drug Conjugates Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Antibody Drug Conjugates Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Seagen
  • 7.2: Takeda Pharmaceutical Company
  • 7.3: AstraZeneca
  • 7.4: F. Hoffmann-La Roche
  • 7.5: Pfizer
  • 7.6: Gilead Sciences
  • 7.7: Daiichi Sankyo Company
  • 7.8: GlaxoSmithKline
  • 7.9: Astellas Pharma
  • 7.10: ADC Therapeutics